The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study.

OBJECTIVE: The study compared the efficacy of methylprednisolone with that of promethazine for the treatment of hyperemesis gravidarum. STUDY DESIGN: Patients with a normal-appearing intrauterine pregnancy of < or = 16 weeks' gestation with hyperemesis gravidarum (persistent vomiting and large ketonuria despite outpatient therapy) were admitted to the hospital for continuous intravenous hydration and offered participation in the study. Patients meeting study criteria were randomly assigned to receive (from identical-appearing dispensers packaged in advance with a 2-week supply) oral methylprednisolone, 16 mg 3 times daily, or oral promethazine, 25 mg 3 times daily. After 3 days the methylprednisolone was tapered completely during the course of 2 weeks whereas the promethazine was continued without change for 2 weeks. For patients who continued to vomit after 2 days the study medication was discontinued. Patients receiving study medication at discharge continued to take the remainder of the assigned medication from the packaged pill dispensers. Patients were followed up weekly. The study outcomes, as established in advance, were (1) improvement of symptoms within 2 days of starting therapy and (2) readmission for hyperemesis within 2 weeks of starting the study. RESULTS: Forty patients were enrolled in the course of 11 months (20 per group). There were no significant differences between the groups with respect to maternal age, gravidity, parity, gestational age at entry, number of previous admissions, or > 5% body weight loss. Three patients in the methylprednisolone group and 2 in the promethazine group failed to stop vomiting within 2 days. One patient from the promethazine group was unavailable for follow-up. No patient from the methylprednisolone group but 5 of the 17 patients receiving promethazine were readmitted for hyperemesis within 2 weeks of discharge (P = .0001). There were no adverse effects noted for either drug. CONCLUSION: A short course of methylprednisolone is more effective than promethazine for the treatment of hyperemesis.

Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum.

OBJECTIVE: Our purpose was to describe the effect of oral methylprednisolone on the course of refractory hyperemesis gravidarum. STUDY DESIGN: Patients with intractable hyperemesis gravidarum were candidates for oral methylprednisolone. Forty-eight milligrams per day was given for 3 days followed by a tapering dose over 2 weeks. If vomiting recurred after 2 weeks of therapy or during tapering, the medication was restarted or extended but not longer than 1 month total. RESULTS: Seventeen of 18 patients (94%) were free of vomiting and were able to tolerate a regular diet within 3 days. Seven did not have further symptoms during their pregnancies. Nine vomited during or after tapering, but 7 of these responded to extension or reinstitution of therapy. Four of 6 patients on total parenteral nutrition at the start of therapy had a complete response within 3 days. CONCLUSIONS: A short course of oral methylprednisolone appears to be a reasonable therapeutic alternative for intractable hyperemesis.

The accuracy of intrapartum ultrasonographic fetal weight estimation in diabetic pregnancies.

OBJECTIVE: Our purpose was to compare the accuracy of ultrasonographic fetal weight estimation in pregnant diabetic women with that of matched nondiabetic controls. STUDY DESIGN: We performed a case-control study of pregnant patients who underwent ultrasonographic fetal weight estimation within 3 days of delivery. The study group consisted of pregnant diabetic women and nondiabetic controls matched for maternal body mass index and neonatal birth weight. Fetal weight estimates were calculated with use of Hadlock's and Shepard's formulas. The difference between ultrasonographic fetal weight estimation and actual birth weight (absolute percent error) was analyzed with respect to maternal diabetic status and actual birth weight. RESULTS: A total of 450 patients were studied (225 patients in each group). The mean (+/- SD) gestational age at delivery was 39.0 +/- 1.5 weeks versus 39.9 +/- 1.7 weeks for the diabetic and nondiabetic patients, respectively. There was no statistically significant difference between the two groups with respect to the mean (+/- SD) time interval between the ultrasonographic examination and delivery (0.9 +/- 1.8 days vs 0.8 +/- 2.1 days) or the mean (+/- SD) absolute percent error (9.0% +/- 7.1% vs 8.4% +/- 6.3%). The mean (+/- SD) absolute percent error of fetal weight estimates among subjects with macrosomic fetuses (birth weight > or = 4500 gm) was significantly greater than that observed in fetuses with birth weights < 4500 gm (12.6% +/- 8.4% vs 8.4% +/- 6.5, p = 0.001). This difference was observed irrespective of maternal diabetic status. CONCLUSION: When matched for maternal body mass index and birth weight, the accuracy of ultrasonographic fetal weight estimation was similar among diabetic and nondiabetic women. Birth weights > or = 4500 gm rather than maternal diabetes seem to be associated with less accurate ultrasonographic fetal weight estimates.

Ultrasonographic fetal cardiac measurement in isoimmunized pregnancies.

OBJECTIVE: To investigate the predictive value of the ultrasonographically measured fetal biventricular outer dimension (BVOD) in diastole in detecting neonatal anemia in pregnancies complicated by isoimmunization. STUDY DESIGN: The records of all patients evaluated for isoimmunization in pregnancy from January 1992 to December 1994 were reviewed retrospectively. The fetal BVOD had been measured with real-time-directed M-mode fetal echocardiography. The BVOD measurement was plotted on a nomogram (with reference to biparietal diameter) and a percentile value determined graphically from the nomogram. Neonatal outcome was obtained prospectively and by chart review. RESULTS: Sixty-three singleton fetuses from the study period who met entry criteria were identified. Anti-D sensitization represented 66% of cases of isoimmunization. Twenty (32%) fetuses required subsequent neonatal transfusion, and 43 (68%) did not. Seventeen fetuses (27%) had BVOD measurements greater than the 95th percentile, and 10 (59%) required subsequent transfusion. Infants in this group also had significantly lower hematocrits at birth (37.7 +/- 13.0% vs. 46.6 +/- 9.0%) and prolonged neonatal intensive care unit stay (10.7 +/- 10.0 vs. 4.7 +/- 3.6 days), respectively, when compared to patients with a BVOD measurement less than the 95th percentile. A BVOD 95th percentile threshold had a sensitivity, specificity and positive predictive value of 50%, 84% and 59%, respectively, in predicting the need for neonatal transfusion. CONCLUSION: In patients with isoimmunization, a BVOD measurement in the 95th percentile or greater was associated with a relatively high likelihood of neonatal anemia and transfusion. Although the measurement is not sufficiently sensitive to be used as a single parameter in predicting neonatal compromise in these patients, it can be a useful, noninvasive adjunct to the management of isoimmunized pregnancies.

Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management.

OBJECTIVE: Our goal was to compare the pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy managed expectantly with antepartum testing with those of other patients who were followed up with a similar testing scheme. STUDY DESIGN: Cases of intrahepatic cholestasis of pregnancy monitored with antepartum testing at our institution over a 7-year period were reviewed. Their pregnancy outcomes were compared with those of control patients followed up with the same testing scheme for a history of stillbirth. Both groups had at least weekly nonstress tests and amniotic fluid assessment until spontaneous labor or delivery for standard obstetric indications RESULTS: Seventy-nine patients were analyzed in each group. The two groups did not differ with respect to the mean gestational age at delivery (38.5 vs 38.8 weeks), birth weight (3216 vs 3277 gm) or incidence of preterm delivery (14% vs 7.6%). Abnormal antepartum testing prompting delivery was more common in the control group (25% vs 7.6%, p < 0.05). The risk of meconium passage was higher in the cholestasis group (44.3% vs 7.6%, p < 0.05). Two antepartum fetal deaths occurred in the cholestasis group at 36 to 37 weeks' gestation within 5 days of normal results of antepartum testing. Thick meconium and appropriate birth weight were noted in both infants. No gross anomalies were found in either infant. CONCLUSION: Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcome not predicted by conventional fetal surveillance.

Clinical significance of prenatal ultrasonographic intestinal dilatation in fetuses with gastroschisis.

OBJECTIVE: Our purpose was to evaluate the clinical significance of intestinal dilatation detected by prenatal ultrasonographic examination in fetuses with gastroschisis. STUDY DESIGN: A retrospective chart review was performed of all patients cared for at Los Angeles County/University of Southern California Women's and Children's Hospital with the prenatal diagnosis of gastroschisis over a 7-year period (1988 through 1995). Patients were divided into two groups on the basis of the presence or absence of ultrasonographically measured fetal bowel diameter of > or = 17 mm. Neonatal outcomes of the two groups were compared. RESULTS: Twenty-one patients met the entry criteria during the study period. Fetuses with maximal bowel diameter of > or = 17 mm did not have a longer time to full oral feeding, a longer initial hospital stay, or a greater need for bowel resection when compared with fetuses with a bowel diameter < 17 mm. Two newborns underwent bowel resection because of intestinal atresia. Prenatal ultrasonographic examination failed to show significant bowel dilatation in either infant. CONCLUSION: Our data suggest that prenatal evidence of intestinal dilatation in fetuses with gastroschisis does not predict immediate neonatal outcome. Thus this finding is not an appropriate indication for preterm delivery in the absence of other evidence of fetal compromise.

Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome.

BACKGROUND: Usually, preeclampsia is a disease of the second half of pregnancy (i.e., beyond 20 weeks' gestation). Early-onset preeclampsia has been reported in association with the antiphospholipid syndrome, however, the cases reported have been at 25-30 weeks' gestation. CASES: Three pregnant women presented with clinical and laboratory features of severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) before 20 weeks' gestation. On evaluation, they were found to have antiphospholipid antibodies (anticardiolipin and/or lupus anticoagulant). Two of the patients had abdominal computed tomography scans that showed a low-density area along the hepatic periphery, compatible with hepatic infarction. Spontaneous resolution of all clinical and laboratory manifestations of preeclampsia and HELLP syndrome was observed after fetal death and pregnancy termination. CONCLUSION: Preeclampsia and HELLP syndrome can present before 20 weeks' gestation in association with the antiphospholipid syndrome and may be associated with hepatic infarction.

The nonreactive nonstress test: predictive value for neonatal anemia in the isoimmunized pregnancy.

OBJECTIVE: To assess the value of the fetal nonstress test (NST) in predicting neonatal transfusion in pregnancies complicated by red cell isoimmunization. METHODS: We retrospectively reviewed the records of all patients evaluated for isoimmunization in pregnancy for the period January 1992 to December 1994. In addition to prenatal care, serial ultrasonography, and invasive testing when indicated, patients had NSTs two times per week. Nonstress tests were interpreted as either reactive or nonreactive using standard criteria. Results of the last NST before delivery were analyzed. Neonatal outcome data were obtained prospectively and by chart review. RESULTS: Sixty patients with isoimmunization were identified during the study period. Fifty-one patients (85%) had reactive NSTs until delivery, and nine (15%) had nonreactive NSTs that prompted delivery. Twelve of 51 (23.5%) patients with reactive NSTs and seven of nine (77.8%) patients with nonreactive NSTs required neonatal transfusion (P = .003, odds ratio 11.4 [95% confidence interval (CI) 1.7-120.2]). The mean (standard error of the mean; range) hematocrit (%) at birth was 38.9 (3.0; 21.3-52.0) in patients with reactive NSTs and 28.3 (3.8; 14.5-45.0) in those with nonreactive NSTs (P < .05). A nonreactive NST had a 77.8% positive predictive value (95% CI 49.0-100) in identifying the need for neonatal transfusion. CONCLUSION: These findings indicate that a nonreactive NST is predictive of subsequent neonatal transfusion in patients with isoimmunization. The antepartum fetal NST is a useful adjunct in the management of isoimmunized pregnancies.